These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1521 related articles for article (PubMed ID: 16287954)

  • 1. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].
    Scheen AJ
    Rev Med Liege; 2006 Jan; 61(1):53-9. PubMed ID: 16491550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
    Stoekenbroek RM; Boekholdt SM; Fayyad R; Laskey R; Tikkanen MJ; Pedersen TR; Hovingh GK;
    Heart; 2015 Mar; 101(5):356-62. PubMed ID: 25595417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thoughts about the results of the "IDEAL" study].
    Kalina A
    Orv Hetil; 2006 May; 147(21):993-5. PubMed ID: 16812974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
    Pedersen TR; Cater NB; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Lindahl C; Szarek M
    Am J Cardiol; 2010 Aug; 106(3):354-9. PubMed ID: 20643245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
    Arca M; Gaspardone A
    Drugs; 2007; 67 Suppl 1():29-42. PubMed ID: 17910519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
    März W; Wollschläger H; Klein G; Neiss A; Wehling M
    Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
    JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
    Strandberg TE; Holme I; Faergeman O; Kastelein JJ; Lindahl C; Larsen ML; Olsson AG; Pedersen TR; Tikkanen MJ;
    Am J Cardiol; 2009 May; 103(10):1381-5. PubMed ID: 19427432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
    Zhao SP; Yu BL; Peng DQ; Huo Y
    Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
    de Lemos JA; Blazing MA; Wiviott SD; Lewis EF; Fox KA; White HD; Rouleau JL; Pedersen TR; Gardner LH; Mukherjee R; Ramsey KE; Palmisano J; Bilheimer DW; Pfeffer MA; Califf RM; Braunwald E;
    JAMA; 2004 Sep; 292(11):1307-16. PubMed ID: 15337732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
    Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC; Pedersen TR; Kastelein JJ;
    Circ Cardiovasc Genet; 2012 Feb; 5(1):51-7. PubMed ID: 22135385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
    Wiviott SD; de Lemos JA; Cannon CP; Blazing M; Murphy SA; McCabe CH; Califf R; Braunwald E
    Circulation; 2006 Mar; 113(11):1406-14. PubMed ID: 16534008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.